Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

163
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
163
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

128
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
128
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

215
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
215
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

208
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
208

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026
Same author

Polyolefin cyclization triggered by electrochemically generated alkoxycarbenium ions: batch and flow conditions.

Chemical science·2026
Same author

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same author

Revisiting Stereocontrol through Ligand-Directed Non-Covalent Interactions in the Asymmetric Synthesis of Tetrahydrofuran Cores via Tsuji-Trost Asymmetric Allylic Alkylation.

ACS omega·2026
Same author

CALPUCK: An Open Python Tool for Cremer-Pople Ring Puckering Analysis Including a New 2D Mapping of Seven-Membered Rings.

ChemPlusChem·2026
Same author

Pro-inflammatory intestinal Th17-cells are tissue-resident, accumulate in the epithelia in Crohn's disease, and predict unresponsiveness to vedolizumab.

Journal of Crohn's & colitis·2026

相关实验视频

Updated: May 24, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K

纳米启用MbtI抑制剂用于下一代结核病治疗.

Giulia Cazzaniga1,2, Matteo Mori1, Anna Griego1,3

  • 1Department of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy.

Journal of medicinal chemistry
|March 3, 2025
PubMed
概括

研究人员开发了针对Mycobacterium tuberculosis (Mtb) 关键酶的新化合物. 这些新型药物显示出有前途的抗结核活性,并使用聚合体进行了输送,为结核病治疗提供了新的策略.

更多相关视频

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

5.6K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K

相关实验视频

Last Updated: May 24, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K
Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

5.6K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.7K

科学领域:

  • 药用化学 医学化学
  • 药物发现 药物发现 药物发现
  • 结核病研究 结核病研究

背景情况:

  • 结核病 (TB) 仍然是一个全球性卫生挑战,需要新的治疗策略.
  • 针对人类缺少的重要Mycobacterium结核病 (Mtb) 酶,为选择性药物开发提供了一条道路.
  • 结核菌酸盐合成酶 (MbtI) 是一个验证的目标,对Mtb病毒性至关重要.

研究的目的:

  • 设计,合成和评估作为MbtI抑制剂的新型5-phenylfuran-2-carboxylic 酸衍生物.
  • 优化化合物,以提高抗结核活性和有利的安全性.
  • 研究聚合体在针对性地提供抗结核药物的潜力.

主要方法:

  • 基于结构的药物设计和合成5-phenylfuran-2-carboxylic 酸衍生物.
  • 酶抑制试验以确定与MbtI.I.相比的IC50值.
  • 在体外对M. bovis BCG进行抗结核活性测试.
  • 优化化合物的封装成多-2-甲基烯酸氧乙烯酸化胆) -多2-二二烯酸) 乙烯基甲基烯酸盐) (PMPC-PDPA) 聚合体 (PO).

主要成果:

  • 确定了几种具有显著抗结核活性的强效MbtI抑制剂.
  • 优化的化合物5-(3-cyano-5-isobutoxyphenyl) furan-2-carboxylic acid (1e) 显示出强烈的MbtI抑制 (IC50 = 11.2 μM) 和体外活性 (MIC99 = 32 μM).
  • 1e的子被成功加载到PMPC-PDPA聚合体中,并在细胞内输送时显示出减少了Mtb的活力.

结论:

  • 新型的5-phenylfuran-2-carboxylic 酸衍生物是有效的 MbtI 抑制剂,具有有前途的抗结核特性.
  • 聚合体作为一种有效的药物输送系统,用于向细胞内菌根菌.
  • 这项研究为开发使用基于聚合体的结核病药物输送的针对MbtI的治疗奠定了基础.